NeuroSense Therapeutics Ltd. (NRSNW) Operating cash flow 2021–2025
NeuroSense Therapeutics Ltd. (NRSNW) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$7.7MFY2025 · since FY2021: -$1.5M → -$7.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$7.7M | +24.3% |
| FY2024 | -$10.1M | -21.3% |
| FY2023 | -$8.4M | -9.7% |
| FY2022 | -$7.6M | -394.9% |
| FY2021 | -$1.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More NRSNW financial trends
NRSNW RevenueNRSNW Net incomeNRSNW Net marginNRSNW Gross profitNRSNW Gross marginNRSNW Operating incomeNRSNW Operating marginNRSNW Free cash flowNRSNW Capital expendituresNRSNW Return on equityNRSNW Stock buybacksNRSNW Dividends paidNRSNW Total assetsNRSNW Total liabilitiesNRSNW Shareholders’ equityNRSNW overview →